Idorsia confirms 2019 spending plan as clinical trials "on track"


ZURICH, April 18 () - Swiss biotech Idorsia said on Thursday that all four clinical trials of its late-stage drug hopefuls were "on track" as it confirmed expectations of spending 570 million Swiss francs ($564 million) in the current year on the projects.

Idorsia's first-quarter net loss widened to 106 million francs, from 79 million in the period in 2018. The Allschwil-based company had total liquidity of 1.1 billion francs as of March 31, down from 1.2 billion at the end of last year.

Shares in the company were down 2.6 percent at 0716 GMT.

Clozel has said "stay tuned" for possible deals, including outlicensing, with other drugmakers as his pipeline matures.

"For every Phase 3 program, there are activities ongoing across the whole company to prepare the comprehensive dossier required by the health authorities," Clozel said. "We have the right professionals who know exactly what it takes to register a drug and to market it successfully."

Idorsia was spun out of Clozel's first company, hypertension specialist Actelion, when he sold it to Johnson & Johnson in 2017 for $30 billion. J&J remains Idorsia's second-biggest shareholder with an 8 percent stake, after Clozel and his wife, Martine, the company's chief scientific officer, who own 28.4 percent.

($1 = 1.0099 Swiss francs)

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics



Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at and via Reuters TV.

Learn More